A newly formed spin-off of GammaDelta Therapeutics in London. Adaptate is developing new treatments for cancer, both haematological and solid tumors, using novel antibodies targeting γδ T cells. Unlike GammaDelta Therapeutics whose focus is on the development of cell based therapies, Adaptate Biotherapeutics will carve out a distinct but related area of science by developing non cell based therapies using antibodies.
Location | London, UK |
CEO | Natalie Mount |
Partner | Tim Haines |
Website | www.adaptatebiotx.com |